LIMN

Liminatus Pharma Inc

Apr 02 • 04:00PM ET

0.1750

+0.0040 2.34 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	79.47%	Shs Outstand	27.06M	Perf Week	-10.30%
Market Cap	7.85M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	9.21M	Perf Month	-29.15%
Enterprise Value	8.95M	PEG	-	EPS next Q	-	Inst Own	0.81%	Short Float	10.81%	Perf Quarter	-71.31%
Income	-9.88M	P/S	-	EPS this Y	-	Inst Trans	3.65%	Short Ratio	0.11	Perf Half Y	-89.88%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-591.27%	Short Interest	1.00M	Perf YTD	-71.31%
Book/sh	-0.36	P/C	23.09	EPS next 5Y	-	ROE	-	52W High	33.66 -99.48%	Perf Year	-98.06%
Cash/sh	0.01	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	0.17 5.42%	Perf 3Y	-98.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.51% 9.48%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.96%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.05	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.07	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.05	EPS Q/Q	-145.97%	SMA20	-16.90%	Beta	0.63	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-62.17%	Rel Volume	0.06	Prev Close	0.17
Employees	1	LT Debt/Eq	-	Earnings	-	SMA200	-93.37%	Avg Volume	8.76M	Price	0.17
IPO	May 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	485,336	Change	2.34%

Mar-17-26 08:08AM	Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody (GlobeNewswire)
Feb-17-26 08:44AM	Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering (GlobeNewswire) -31.86%
Oct-30-25 10:04AM	Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation (GlobeNewswire)
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +22.66%
Aug-05-25 12:11PM	BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism (CoinDesk)
07:30AM	Loading…
Jul-28-25 07:30AM	Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative (GlobeNewswire) -7.23%
Jul-25-25 08:31AM	Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies (GlobeNewswire)
Jul-24-25 08:31AM	Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy (GlobeNewswire) +30.91%
Jul-22-25 01:30PM	Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy (GlobeNewswire)

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in Cerritos, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIMN

Liminatus Pharma Inc

Upgrade your Finviz experience